Monthly Newsletter

Join Precision NanoSystems for a roundtable discussion on nanomedicines as part of the 3^rd International Electronic Conference on Medicinal Chemistry.

Organised by Pharmaceuticals journal, this free online conference runs until November 30^th, and deals with all aspects of research in drug discovery and development. As a partner of the event, Precision NanoSystems is hosting a virtual roundtable, providing an opportunity to discuss the current hot topics in nanomedicine research and share new insights and recent results with scientists from academic and industrial groups around the world.

Dr Jean Jacques Vanden Eynde, editor-in-chief of Pharmaceuticals, commented: “An international electronic conference allows thousands of researchers to share their results and ideas without having to leave their offices. Our goal when we launched the first International Electronic Conferences on Medicinal Chemistry was to contribute to significant advances in healthcare. This is still the aim of the 2017 edition, which includes an exceptional roundtable on nanomedicines sponsored by Precision Nanosystems,”

The roundtable is moderated by Dr Euan Ramsay, co-founder and COO of Precision NanoSystems, who is joined by Professor Pieter Cullis from the Department of Biochemistry and Molecular Biology at the University of British Columbia, and Professor Dan Peer from the Department of Cell Research and Immunology at Tel Aviv University. The discussion will consider the impact of medicinal chemistry on the clinical development of nucleic acid-lipid nanoparticles, and the development of lipid-based nanoparticles for the delivery of hydrophobic drugs. In addition, all three experts will provide insight into the potential role for medicinal chemistry in realizing the opportunities of targeted nanomedicines.

Learn more about the free 3^rd International Electronic Conference on Medicinal Chemistry

About Precision NanoSystems

Precision NanoSystems Inc. (PNI) creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases.  PNI’s NanoAssemblr™ Transfection Reagents use nanomedicine technology to deliver genetic materials in primary cells in vitro and in vivo, enabling disease researchers to easily study gene function in high-value models of disease. PNI’s proprietary NanoAssemblr™ platform enables the rapid, reproducible, and scalable manufacture of nanoparticle formulations for delivery of nucleic acids, drug molecules, and diagnostic agents to cells and tissues in the body. PNI sells its products to leading pharmaceutical and biotechnology companies, and leading academic institutions in over 20 countries worldwide.

For more information on Precision NanoSystems, visit www.precisionnanosystems.com